Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations

Selective FGFR inhibitors such as infigratinib (BGJ398) and erdafitinib (JNJ-42756493) have been evaluated in clinical trials for cancers with FGFR3 molecular alterations, particularly in urothelial carcinoma patients. However, a substantial proportion of these patients (up to 50%) display intrinsic...

Descripción completa

Detalles Bibliográficos
Autores principales: Lima, Nadia Carvalho, Atkinson, Eliza, Bunney, Tom D., Katan, Matilda, Huang, Paul H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246793/
https://www.ncbi.nlm.nih.gov/pubmed/32370101
http://dx.doi.org/10.3390/ijms21093214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246793/
https://www.ncbi.nlm.nih.gov/pubmed/32370101
http://dx.doi.org/10.3390/ijms21093214

Ejemplares similares